00:00Adding a personalized mRNA vaccine was linked to a 42% lower risk of melanoma returning.
00:06The results come from the Phase 3 InterPATH-001 trial, presented at the ESMO Congress 2026.
00:13It enrolled 1137 adults after surgery for high-risk melanoma.
00:18Patients received the immunotherapy Pembrolizumab, with either the vaccine or a placebo.
00:24Each vaccine encodes up to 34 abnormal proteins from the patient's own tumor.
00:29That helps the immune system find and attack any remaining cancer cells.
00:33At two years, 82.2% on the combination were alive without recurrence.
00:39That compared with 70.0% on immunotherapy alone, the risk of distant spread or death was 38% lower.
00:47Overall survival data are still immature, and longer follow-up is needed.
00:51Fever, injection site pain, and fatigue were the most common side effects.
00:55Trials are already underway in lung, bladder, and kidney cancer.
00:59It is the first Phase 3 study to show a tumor-built treatment can lower this risk.
01:04Disclosure.
01:05This video contains stock footage and content created or enhanced using AI-assisted tools.
01:09human
01:09with
01:09Service 6 study.
01:10The
